Lassa fever can present with a wide range of symptoms, making it challenging to diagnose based solely on clinical presentation. The incubation period is typically 6 to 21 days. Initial symptoms are often non-specific and may include fever, general weakness, and malaise. As the disease progresses, patients may experience headaches, sore throat, muscle pain, chest pain, nausea, vomiting, diarrhea, cough, and abdominal pain. In severe cases, symptoms can escalate to facial swelling, fluid in the lung cavity, bleeding from the mouth, nose, or gastrointestinal tract, and low blood pressure. Hearing loss is a common complication in survivors.

Diagnosing Lassa fever requires a combination of clinical assessment and laboratory testing. Due to its non-specific symptoms, laboratory confirmation is essential. Blood tests can detect the virus or its antibodies. Reverse transcription-polymerase chain reaction (RT-PCR) is a common method used to identify the virus's genetic material. Enzyme-linked immunosorbent assay (ELISA) can detect Lassa virus antibodies or antigens. It is crucial to handle samples with care to prevent laboratory transmission.

There is no specific antiviral treatment for Lassa fever, but early supportive care with rehydration and symptomatic treatment improves survival. Ribavirin, an antiviral drug, has been used with some success, especially when administered early in the course of the disease. Patients may require hospitalization for intensive care, including fluid management, blood transfusions, and treatment of secondary infections. Supportive care is critical to managing symptoms and preventing complications.

The prognosis for Lassa fever varies. Approximately 80% of infections are mild or asymptomatic, but the remaining 20% can be severe. The overall case-fatality rate is about 1%, but it can reach 15% among hospitalized patients. Early diagnosis and treatment significantly improve outcomes. Pregnant women, especially in the third trimester, and individuals with pre-existing conditions are at higher risk of severe disease and complications.

Lassa fever is caused by the Lassa virus, a single-stranded RNA virus. The primary reservoir of the virus is the multimammate rat (Mastomys natalensis), which is widespread in West Africa. Humans become infected through direct contact with the rodent's excreta or through consumption of contaminated food. Person-to-person transmission can occur through direct contact with the blood, tissue, secretions, or excretions of an infected individual, particularly in healthcare settings.

Lassa fever is endemic in West Africa, with an estimated 100,000 to 300,000 infections and about 5,000 deaths annually. The disease is most prevalent in rural areas where Mastomys rats are common. Outbreaks occur sporadically, often linked to increased rodent populations. Healthcare workers are at risk during outbreaks due to potential exposure to infected patients. The disease's geographic distribution is expanding, raising concerns about its potential spread to other regions.

Lassa virus primarily targets the liver, spleen, and kidneys. After entering the body, the virus replicates in various cells, leading to cell damage and inflammation. The immune response to the virus can cause further tissue damage. In severe cases, the virus can affect the vascular system, leading to increased vascular permeability and bleeding. The exact mechanisms of hearing loss, a common complication, are not fully understood but may involve direct viral damage to the inner ear structures.

Preventing Lassa fever involves reducing contact with Mastomys rats and their excreta. This can be achieved by storing food in rodent-proof containers, maintaining clean households, and avoiding contact with rodents. In healthcare settings, strict infection control measures, including the use of personal protective equipment, are essential to prevent nosocomial transmission. Community education on rodent control and hygiene practices is crucial in endemic areas. Currently, there is no licensed vaccine for Lassa fever, but research is ongoing.

Lassa fever is a viral hemorrhagic illness endemic to West Africa, transmitted primarily through contact with infected rodents. It presents with a wide range of symptoms, from mild to severe, and can be fatal if not treated promptly. Diagnosis relies on laboratory testing, and treatment focuses on supportive care and the use of ribavirin. Prevention involves reducing rodent exposure and implementing strict infection control measures. Understanding the disease's epidemiology and pathophysiology is key to managing and preventing outbreaks.

Lassa fever is a disease caused by a virus found in certain rats in West Africa. People can get sick if they come into contact with the rats or their droppings. Symptoms can start like the flu but can become more serious, with bleeding and organ problems. If you live in or travel to areas where Lassa fever is common, it's important to keep food away from rats and maintain good hygiene. If you feel sick after being in these areas, see a doctor quickly. Early treatment can help you recover better.